Hans Verbaan

Infliximab as Rescue Therapy in Severe to Moderately Severe Ulcerative Colitis: A Randomized, Placebo-Controlled Study

Gunnar Järnerot, Erik Hertervig, Ingalill Friis–Liby et al. · Gastroenterology · 2005 · 1.1K citations · Full text

Pharmacy, Immunology, Pharmacotherapy +15

A Risk for Hepatocellular Carcinoma Persists Long-term After Sustained Virologic Response in Patients With Hepatitis C–Associated Liver Cirrhosis

Soo Aleman, Nogol Rahbin, Ola Weiland et al. · Clinical Infectious Diseases · 2013 · 233 citations · Full text

Medicine, Infectious Diseases, Hepatology +16

Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response

Olav Dalgård, Kristian Bjro, Helmer Ring‐Larsen et al. · Hepatology · 2007 · 208 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Clinical trial: colectomy after rescue therapy in ulcerative colitis – 3‐year follow‐up of the Swedish‐Danish controlled infliximab study

A. Gustavsson, G Järnerot, Erik Hertervig et al. · Alimentary Pharmacology & Therapeutics · 2010 · 180 citations

Pharmacy, Pharmacotherapy, Surgery +12

IL28B Genetic Variation and Treatment Response in Patients with Hepatitis C Virus Genotype 3 Infection σ

Amir Moghaddam, Espen Melum, Nils Reinton et al. · Hepatology · 2011 · 127 citations

Life Sciences, Genetics, Immunology +17